CER advocates and even Patient Centered Outcomes Research Institute committee members push the healthcare system to embrace data-dredging of the lowest form. See the article from Drug Benefit News where the one size fits all CER crowd extols the virtues of poorly powered head to head studies included in FDA submissions as a 'treasure trove' of data for driving prescribing decisions and guidance. A study by Joshua Gagne ,Sebastian Schneerweis ( a member of the PCORI methodology committee) are drooling over the possibility of using such data to shape what drugs we can use and when.
The Harvard researchers were taken aback, he says, to discover so many drugs had CER on file. “We were also surprised by how many actually had defective comparator data,” Gagne says. “So even though our study suggested that 70% actually had data available, it doesn’t necessarily guide coverage decisions for 70% of the drugs.”
Note to Gagne and PCORI committee member Schneerweis: CER is not supposed to be used to guide coverage decisions. Or maybe they didn't read the statute.
aishealth.com/archive/ndbn051311-04
By contrast the Association of the British Pharmaceutical Industry has published a document for using real world data to guide treatment selection that the PCORI and CER crowd should pay attention to.
It takes up to three years after a drug gets approved by Britian's Medicine Agency to get through CER review and onto market. Are we willing to make such delay part and parcel of health care reform?
The Harvard researchers were taken aback, he says, to discover so many drugs had CER on file. “We were also surprised by how many actually had defective comparator data,” Gagne says. “So even though our study suggested that 70% actually had data available, it doesn’t necessarily guide coverage decisions for 70% of the drugs.”
Note to Gagne and PCORI committee member Schneerweis: CER is not supposed to be used to guide coverage decisions. Or maybe they didn't read the statute.
aishealth.com/archive/ndbn051311-04
By contrast the Association of the British Pharmaceutical Industry has published a document for using real world data to guide treatment selection that the PCORI and CER crowd should pay attention to.
It takes up to three years after a drug gets approved by Britian's Medicine Agency to get through CER review and onto market. Are we willing to make such delay part and parcel of health care reform?
